
    
      This is a randomized, double-blind, multicenter, placebo-controlled trial to compare the
      efficacy and safety of pregabalin SR vs placebo in patients with PHN.

      The study is conducting at 27 study centers in China. Patients were randomized to receive
      pregabalin, starting at 165 mg/day and increasing to a maintenance dose of 330 or 660 mg/day,
      or placebo.

      The study includes a 1-week, single-blind, placebo run-in period; a 2-week
      dose-escalation/optimization phase; a 12-week, fixed-dose treatment period; and a 1-week
      taper phase.
    
  